Anne W. Beaven, MD
Department / Division
Medicine /
Medicine - Oncology
Address
DUMC 3872
Durham, NC 27710
Appointment Telephone
919-684-8964
Office Telephone
919-684-8964
Fax Telephone
919-684-5325
- MD, University of North Carolina at Chapel Hill School of Medicine, 2000
- Internal Medicine, UNC Hospitals, 2000-2003
- Hematology/Oncology, UNC Hospitals, 2004-2007
Clinical Interests
Treatment of hematologic malignancies, clinical trials in lymphoma
Research Interests
My particular area of research interest is clinical trails for patients with lymphoma.
This physician (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.
- Allos Therapeutics, Inc.
- Cephalon, Inc.
- GlaxoSmithKline
Representative Publications
Beaven AW, Moore DT, Sharf A, Serody JS, Shea TC, Gabriel DA. Infusional mitoxantrone plus bolus melphalan as a stem cell transplant conditioning regimen for multiple myeloma. Cancer Invest. 2011 Mar;29(3):214-9.
(2011)
Abstract
Beaven AW, Shea TC, Moore DT, Feldman T, Ivanova A, Ferraro M, Ford P, Smith J, Goy A. A phase I study evaluating ibritumomab tiuxetan (Zevalin(®)) in combination with bortezomib (Velcade(®)) in relapsed/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma. Leuk Lymphoma. 2011 Sep 19.
(2011)
Abstract
Dorth JA, Chino JP, Prosnitz LR, Diehl LF, Beaven AW, Coleman RE, Kelsey CR. The impact of radiation therapy in patients with diffuse large B-cell lymphoma with positive post-chemotherapy FDG-PET or gallium-67 scans. Ann Oncol. 2011 Feb;22(2):405-10.
(2011)
Abstract
Kelsey CR, Beaven AW, Diehl LF, Prosnitz LR. Radiation therapy in the management of diffuse large B-cell lymphoma: still relevant? Oncology (Williston Park). 2010 Nov 30;24(13):1204-12.
(2010)
Abstract
Shea TC, Beaven AW, Moore DT, Serody JS, Gabriel DA, Chao N, Gockerman JP, Garcia RA, Rizzieri DA. Sequential high-dose ifosfamide, carboplatin and etoposide with rituximab for relapsed Hodgkin and large B-cell non-Hodgkin lymphoma: increased toxicity without improvement in progression-free survival. Leuk Lymphoma. 2009 May;50(5):741-8.
(2009)
Abstract
